Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pfizer Inc. is conducting a Phase 4 study titled ‘A Phase 4 Study Using a Test-Negative Design to Evaluate the Effectiveness of a 20-valent Pneumococcal Conjugate Vaccine Against Vaccine-type Radiologically-confirmed Community-acquired Pneumonia in Adults >/= 65 Years of Age.’ The study aims to assess the effectiveness of the 20-valent pneumococcal conjugate vaccine (20vPnC) in preventing pneumonia caused by specific strains of Streptococcus pneumoniae in adults aged 65 and older. This research is significant as it seeks to provide real-world evidence of the vaccine’s efficacy in preventing serious pneumonia cases.
The intervention being tested is a diagnostic test on urine samples to detect pneumococcal strains using BinaxNOW® S. pneumoniae and serotype-specific urinary antigen detection assays. This test is crucial for identifying the presence of the bacteria in vaccinated individuals.
The study is observational with a case-control model and a prospective time perspective. Participants are divided into ‘Case’ and ‘Control’ groups based on the presence of specific pneumococcal serotypes. The primary purpose is to evaluate vaccine effectiveness in a real-world setting.
The study began on July 6, 2022, and is currently recruiting participants. The primary completion and estimated completion dates are yet to be announced, with the last update submitted on June 26, 2025. These dates are essential for tracking the study’s progress and anticipating results.
This study could impact Pfizer’s stock performance positively by demonstrating the vaccine’s effectiveness, potentially increasing investor confidence. In the broader industry context, successful results could enhance Pfizer’s competitive position in the pneumococcal vaccine market.
The study is ongoing, and further details are available on the ClinicalTrials portal.